Skip to main content

Anixa Biosciences CEO Amit Kumar Discusses "How the Pandemic Has Impacted the Company and Finding a Cure for Covid-19" on TD Ameritrade Network

Anixa Biosciences and OntoChem Recently Announced The Discovery of First Covid-19 Therapeutic Candidate

Rochester, NY -- (ReleaseWire) -- 05/07/2020 -- Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Discusses How The Pandemic Has Impacted The Company And Finding A Cure For Covid-19

The Watch List with Nicole Petallides offers investors a midday look at the most relevant stocks, sectors and commodities. Petallides hosts a panel of experts ranging from industry-leading CEOs, analysts and Wall Street influencers to discuss pressing topics moving the market in real-time. The Watch List provides viewers with a midpoint status update for the end of the trading day and beyond.

Watch The Interview By Clicking The Link Below:
CEO Amit Kumar Discusses How The Pandemic Has Impacted The Company And Finding A Cure For Covid-19

Recent News:

Anixa Biosciences (NASDAQ:ANIX) and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate

https://ir.anixa.com/press-releases/detail/949/anixa-biosciences-and-ontochem-announce-discovery-of-first

About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against ?-Lactalbumin to prevent triple negative breast cancer (TNBC), a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's diagnostic portfolio consists of Cchekâ„¢, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.

About OntoChem GmbH
OntoChem GmbH is a German based company which is specialized in chemo- and bio-IT services. As a data-driven company, OntoChem is using AI techniques to answer project specific questions and is supporting scientists to discover knowledge in the life sciences eco-system. OntoChem is located in Halle (Saale) and Stuttgart. Having started in 2005, the team has a long history of developing and applying ontologies, software tools and data streams for life and material science customers. More on OntoChem at www.ontochem.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808

Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694

Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686

SOURCE Anixa Biosciences, Inc.

Disclaimer:
We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on this page unless you can afford to lose your entire investment. InvestorNewsSource and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. InvestorNewsSource is compensated by third party shareholders to feature certain companies. These third parties may have shares and may liquidate the company's shares which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Investor News Source may, from time to time, purchase shares of public companies that we have been compensated to feature or profile in the open market and Investor News Source does this at fair market value. Release of Liability: Through use of this advertisement page viewing or using you agree to hold InvestorNewsSource its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the Information. This is not a solicitation to buy stock.

For more information on this press release visit: http://www.releasewire.com/press-releases/anixa-biosciences-ceo-amit-kumar-discusses-how-pandemic-1290226.htm

Media Relations Contact

Derek C McCarthy
Editor
Investor News Source
Telephone: 216-246-5006
Email: Click to Email Derek C McCarthy
Web: https://tdameritradenetwork.com/video/rB4AoXHUFCyBceaKZaQFuw

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.